For the Inventor, By the Inventor

Enter assignee name

Miami, FL, United States of America

Opko Health, Inc.

USPTO Granted Patents = 26

% Expired Patents = 7.7

CIPO Patents = 1

EPO Patents = 10

Forward Citations = 155

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Sunil Paliwal (15 out of 28 patents)

Neng-Yang Shih (15 out of 110 patents)

Hon-Chung Tsui (12 out of 19 patents)

4. Dong Xiao (9 out of 46 patents)

5. Anandan Palani (9 out of 71 patents)

6. Michelle Laci Wrobleski (9 out of 12 patents)

7. Cheng Wang (9 out of 26 patents)

8. Ingrid Mergelsberg (8 out of 8 patents)

9. Xianhai Huang (5 out of 53 patents)

10. Sapna S Shah (5 out of 6 patents)

11. Ashwin Umesh Rao (5 out of 19 patents)

12. Gregory A Reichard (4 out of 21 patents)

13. Juan D Arredondo (4 out of 5 patents)

14. Zhihui Qiu (4 out of 7 patents)

15. Mengwei Hu (3 out of 4 patents)

Core Competencies:

Hydrochloride Salts

Pharmaceutical Formulations

NK1 Antagonists

Neurodegenerative Diseases

Tablet Formulations

Oral Dosage

Synthesis Process

Small Molecules

26 patents: Sort by Forward Citations

1. 10196394 - Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor (2019-02-05),

2. 10000493 - Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds (2018-06-19),

3. 9969711 - [object Object] (2018-05-15),

4. 9822116 - Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds (2017-11-21),

5. 9688693 - [object Object] (2017-06-27),

6. 9551721 - Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases (2017-01-24),

7. 9469629 - [object Object] (2016-10-18),

8. 9345692 - Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same (2016-05-24),

9. 9260428 - Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds (2016-02-16),

10. 9249144 - Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds (2016-02-02),

11. 9101615 - Intravenous formulations of neurokinin-1 antagonists (2015-08-11),

12. 9006211 - Hypersulfated disaccharide formulations (2015-04-14),

13. 8906410 - Oral dosage form of 25-hydroxyvitamin D (2014-12-09),

14. 8796299 - NK1 antagonists (2014-08-05),

15. 8754216 - NK1 antagonists (2014-06-17),

Company Overview

Opko Health, Inc. is a diversified healthcare company based in Miami, Florida, focusing on the development and commercialization of innovative medical technologies and pharmaceuticals. The company specializes in areas such as diagnostics, therapeutics, and drug delivery systems, aiming to enhance patient care and improve health outcomes. Opko's research initiatives span various therapeutic areas, including endocrinology and oncology, leveraging advanced technologies to address unmet medical needs on a global scale.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

26 Patents

#29 in Miami, FL

#321 in Florida

#12,865 in US

#24,826 in the World

Miami, FL, United States of America

Opko Health, Inc.

Forward Citations = 155

49 inventors:

Sunil Paliwal (15 out of 28 patents)

Neng-Yang Shih (15 out of 110 patents)

Hon-Chung Tsui (12 out of 19 patents)

4. Dong Xiao (9 out of 46 patents)

5. Anandan Palani (9 out of 71 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Opko Health, Inc.. Retrieved from https://idiyas.com/company/opko-health

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…